



Measles NP (3E1): sc-57911

BACKGROUND

Measles virus (MV), also known as rubeola, is an acute viral illness that can be complicated by severe pneumonia, diarrhea, and encephalitis. A paramyxovirus of the genus *Morbillivirus*, Measles virus is an enveloped and nonsegmented negative-stranded RNA virus. Because it is spread through respiration, Measles is highly contagious and airborne precautions should be taken for all suspected cases of Measles. After transmission, the virus infects the epithelial cells of its new host, and may also replicate in the urinary tract, conjunctivae, blood vessels, lymphatic system, and central nervous system. The Measles virus contains two envelope glycoproteins, the haemagglutinin (H) and fusion proteins, which are responsible for membrane fusion and attachment. The nucleoprotein of the Measles virus (Measles NP), also known as a nucleocapsid, is the basic architecture of the virus, comprised of a core of nucleic acid captured in a protein coat.

REFERENCES

1. Warnes, A., Fooks, A.R. and Stephenson, J.R. 1994. Production of Measles nucleoprotein in different expression systems and its use as a diagnostic reagent. *J. Virol. Methods* 49: 257-268.
2. Parks, C.L., Witko, S.E., Kotash, C., Lin, S.L., Sidhu, M.S. and Udem, S.A. 2006. Role of V protein RNA binding in inhibition of Measles virus minigenome replication. *Virology* 348: 96-106.
3. Iankov, I.D., Pandey, M., Harvey, M., Griesmann, G.E., Federspiel, M.J. and Russell, S.J. 2006. Immunoglobulin γ antibody-mediated enhancement of Measles virus infection can bypass the protective antiviral immune response. *J. Virol.* 80: 8530-8540.
4. Yanagi, Y., Takeda, M. and Ohno, S. 2006. Measles virus: cellular receptors, tropism and pathogenesis. *J. Gen. Virol.* 87: 2767-2779.
5. Halsey, N.A. 2006. Measles in developing countries. *BMJ* 333: 1234.
6. Centers for Disease Control and Prevention (CDC). 2006. Measles—United States, 2005. *MMWR Morb. Mortal. Wkly. Rep.* 55: 1348-1351.
7. Bradsher, C.A., Stotts, R.C., Carter, M.A. and Grabowsky, M. 2007. The Measles initiative to control Measles in Kenya. *Public Health Nurs.* 24: 26-33.
8. Vijayaraghavan, M., Martin, R.M., Sangrujee, N., Kimani, G.N., Oyombe, S., Kalu, A., Runyago, A., Wanjau, G., Cairns, L. and Muchiri, S.N. 2007. Measles supplemental immunization activities improve Measles vaccine coverage and equity: evidence from Kenya, 2002. *Health Policy* 83: 27-36.
9. Moss, W.J. 2007. Measles still has a devastating impact in unvaccinated populations. *PLoS Med.* 4: e24.

SOURCE

Measles NP (3E1) is a mouse monoclonal antibody raised against full length recombinant Measles nucleoprotein.

PRODUCT

Each vial contains 100 μ g IgG₁ in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin.

APPLICATIONS

Measles NP (3E1) is recommended for detection of both native and recombinant nucleoprotein of Measles virus origin by Western Blotting (starting dilution 1:200, dilution range 1:100-1:1000) and solid phase ELISA (starting dilution 1:30, dilution range 1:30-1:3000); non cross-reactive with mumps nucleoprotein.

Molecular Weight of Measles NP: 60 kDa.

SELECT PRODUCT CITATIONS

1. Steppert, P., Mosor, M., Stanek, L., Burgstaller, D., Palmberger, D., Preinsperger, S., Pereira Aguilar, P., Müllner, M., Csar, P. and Jungbauer, A. 2022. A scalable, integrated downstream process for production of a recombinant Measles virus-vectored vaccine. *Vaccine*. E-published.

STORAGE

Store at 4° C, ****DO NOT FREEZE****. Stable for one year from the date of shipment. Non-hazardous. No MSDS required.

RESEARCH USE

For research use only, not for use in diagnostic procedures.

PROTOCOLS

See our web site at www.scbt.com for detailed protocols and support products.